ZA200405694B - Novel aryl-and heteroarylpiperazines - Google Patents
Novel aryl-and heteroarylpiperazines Download PDFInfo
- Publication number
- ZA200405694B ZA200405694B ZA2004/05694A ZA200405694A ZA200405694B ZA 200405694 B ZA200405694 B ZA 200405694B ZA 2004/05694 A ZA2004/05694 A ZA 2004/05694A ZA 200405694 A ZA200405694 A ZA 200405694A ZA 200405694 B ZA200405694 B ZA 200405694B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- compound according
- aryl
- alkoxy
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 95
- -1 Ci-0-alkyl Substances 0.000 claims description 75
- 150000002367 halogens Chemical class 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 37
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 102000004384 Histamine H3 receptors Human genes 0.000 claims description 15
- 108090000981 Histamine H3 receptors Proteins 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 12
- 125000003435 aroyl group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 229960001340 histamine Drugs 0.000 claims description 6
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 230000001270 agonistic effect Effects 0.000 claims description 5
- 230000003042 antagnostic effect Effects 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 208000037765 diseases and disorders Diseases 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- AUNLIXPDGQSPGW-UHFFFAOYSA-N (4-fluorophenyl)-[4-(4-pentan-3-ylpiperazin-1-yl)phenyl]methanone Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(C(=O)C=2C=CC(F)=CC=2)C=C1 AUNLIXPDGQSPGW-UHFFFAOYSA-N 0.000 claims description 2
- KLDRCVWDIQOOEC-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-4-pentan-3-ylpiperazine Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(Cl)C(Cl)=C1 KLDRCVWDIQOOEC-UHFFFAOYSA-N 0.000 claims description 2
- UESDDOLQUMWNDH-UHFFFAOYSA-N 1-(3-chlorophenyl)-4-cyclopentylpiperazine Chemical compound ClC1=CC=CC(N2CCN(CC2)C2CCCC2)=C1 UESDDOLQUMWNDH-UHFFFAOYSA-N 0.000 claims description 2
- UKIDNCFCCFYFPT-UHFFFAOYSA-N 1-(4-benzylphenyl)-4-pentan-3-ylpiperazine Chemical compound C1CN(C(CC)CC)CCN1C(C=C1)=CC=C1CC1=CC=CC=C1 UKIDNCFCCFYFPT-UHFFFAOYSA-N 0.000 claims description 2
- GGKVTTJLMXTEHF-UHFFFAOYSA-N 1-cyclopentyl-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CCN(C2CCCC2)CC1 GGKVTTJLMXTEHF-UHFFFAOYSA-N 0.000 claims description 2
- ORYGSMWIIBOVDS-UHFFFAOYSA-N 2-(4-cyclopentylpiperazin-1-yl)-7-methoxy-3-(4-methoxyphenyl)quinoline Chemical compound C1=CC(OC)=CC=C1C1=CC2=CC=C(OC)C=C2N=C1N1CCN(C2CCCC2)CC1 ORYGSMWIIBOVDS-UHFFFAOYSA-N 0.000 claims description 2
- YODKFKAHHFMXKB-UHFFFAOYSA-N 2-(4-cyclopentylpiperazin-1-yl)quinoxaline Chemical compound C1CCCC1N1CCN(C=2N=C3C=CC=CC3=NC=2)CC1 YODKFKAHHFMXKB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- ZLTRDWRTQXIMHI-UHFFFAOYSA-N 4-(4-cyclopentylpiperazin-1-yl)phenol Chemical compound C1=CC(O)=CC=C1N1CCN(C2CCCC2)CC1 ZLTRDWRTQXIMHI-UHFFFAOYSA-N 0.000 claims description 2
- DYGULAKZSWXNAY-UHFFFAOYSA-N 7-chloro-4-(4-pentan-3-ylpiperazin-1-yl)quinoline Chemical compound C1CN(C(CC)CC)CCN1C1=CC=NC2=CC(Cl)=CC=C12 DYGULAKZSWXNAY-UHFFFAOYSA-N 0.000 claims description 2
- GSHXFMNTSJJDCC-UHFFFAOYSA-N [6-(4-cyclopentylpiperazin-1-yl)pyridin-3-yl]-piperidin-1-ylmethanone Chemical compound C=1C=C(N2CCN(CC2)C2CCCC2)N=CC=1C(=O)N1CCCCC1 GSHXFMNTSJJDCC-UHFFFAOYSA-N 0.000 claims description 2
- HHSVDWCVSSZBGI-UHFFFAOYSA-N [6-[4-(2-cyclopropylpropan-2-yl)piperazin-1-yl]pyridin-3-yl]-phenylmethanone Chemical compound C1CN(C=2N=CC(=CC=2)C(=O)C=2C=CC=CC=2)CCN1C(C)(C)C1CC1 HHSVDWCVSSZBGI-UHFFFAOYSA-N 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 3
- 208000032841 Bulimia Diseases 0.000 claims 2
- 102000000543 Histamine Receptors Human genes 0.000 claims 2
- 108010002059 Histamine Receptors Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- JTWJBPGIEVYSGB-UHFFFAOYSA-N 1-cyclopentyl-4-[3-(trifluoromethyl)pyridin-2-yl]piperazine Chemical compound FC(F)(F)C1=CC=CN=C1N1CCN(C2CCCC2)CC1 JTWJBPGIEVYSGB-UHFFFAOYSA-N 0.000 claims 1
- JTYWGWMHLBKKPJ-UHFFFAOYSA-N 1-cyclopentyl-4-[4-[(4-fluorophenyl)methoxy]phenyl]piperazine Chemical compound C1=CC(F)=CC=C1COC1=CC=C(N2CCN(CC2)C2CCCC2)C=C1 JTYWGWMHLBKKPJ-UHFFFAOYSA-N 0.000 claims 1
- DMMRSMPUZJDBFI-UHFFFAOYSA-N 1-cyclopentyl-4-[6-(trifluoromethyl)pyridin-2-yl]piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CC2)C2CCCC2)=N1 DMMRSMPUZJDBFI-UHFFFAOYSA-N 0.000 claims 1
- JGCMOVVEQUHZRT-UHFFFAOYSA-N 2-(4-cyclopentylpiperazin-1-yl)quinoline Chemical compound C1CCCC1N1CCN(C=2N=C3C=CC=CC3=CC=2)CC1 JGCMOVVEQUHZRT-UHFFFAOYSA-N 0.000 claims 1
- MHWHBMVPYRSQGR-UHFFFAOYSA-N 2-(4-cyclopropylpiperazin-1-yl)-6-(trifluoromethyl)quinoline Chemical compound C1=CC2=CC(C(F)(F)F)=CC=C2N=C1N(CC1)CCN1C1CC1 MHWHBMVPYRSQGR-UHFFFAOYSA-N 0.000 claims 1
- FSMPRTRJKQTCLK-UHFFFAOYSA-N 2-(4-cyclopropylpiperazin-1-yl)-6-propylquinoline Chemical compound C1=CC2=CC(CCC)=CC=C2N=C1N(CC1)CCN1C1CC1 FSMPRTRJKQTCLK-UHFFFAOYSA-N 0.000 claims 1
- HEWVIFVVKWCRML-UHFFFAOYSA-N 2-(4-ethylpiperazin-1-yl)quinoline Chemical compound C1CN(CC)CCN1C1=CC=C(C=CC=C2)C2=N1 HEWVIFVVKWCRML-UHFFFAOYSA-N 0.000 claims 1
- CMNVZVJPAQJIHB-UHFFFAOYSA-N 2-(4-pentan-3-ylpiperazin-1-yl)-4-(trifluoromethyl)quinoline Chemical compound C1CN(C(CC)CC)CCN1C1=CC(C(F)(F)F)=C(C=CC=C2)C2=N1 CMNVZVJPAQJIHB-UHFFFAOYSA-N 0.000 claims 1
- GCZGGBYOWDOXHL-UHFFFAOYSA-N 2-[4-(cyclopropylmethyl)piperazin-1-yl]-6-methoxy-4-(trifluoromethyl)quinoline Chemical compound C1=C(C(F)(F)F)C2=CC(OC)=CC=C2N=C1N(CC1)CCN1CC1CC1 GCZGGBYOWDOXHL-UHFFFAOYSA-N 0.000 claims 1
- NHMQRLGETCFQBU-UHFFFAOYSA-N 2-[4-(cyclopropylmethyl)piperazin-1-yl]quinoxaline Chemical compound C1CN(C=2N=C3C=CC=CC3=NC=2)CCN1CC1CC1 NHMQRLGETCFQBU-UHFFFAOYSA-N 0.000 claims 1
- BSEXWLKKPNSFLV-UHFFFAOYSA-N 6,7-dimethoxy-2-(4-pentan-3-ylpiperazin-1-yl)quinoline Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(C=C(OC)C(OC)=C2)C2=N1 BSEXWLKKPNSFLV-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010004716 Binge eating Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 238000004965 Hartree-Fock calculation Methods 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- BIGIOOUWKKVMEI-UHFFFAOYSA-N [3,5-difluoro-4-(4-pentan-3-ylpiperazin-1-yl)phenyl]-(4-fluorophenyl)methanone Chemical compound C1CN(C(CC)CC)CCN1C1=C(F)C=C(C(=O)C=2C=CC(F)=CC=2)C=C1F BIGIOOUWKKVMEI-UHFFFAOYSA-N 0.000 claims 1
- HNBORJOWPIRWFD-UHFFFAOYSA-N [4-(4-cyclopentylpiperazin-1-yl)-3,5-difluorophenyl]-phenylmethanone Chemical compound FC1=CC(C(=O)C=2C=CC=CC=2)=CC(F)=C1N(CC1)CCN1C1CCCC1 HNBORJOWPIRWFD-UHFFFAOYSA-N 0.000 claims 1
- TWLQBZJVBYJZPS-UHFFFAOYSA-N [4-(4-cyclopentylpiperazin-1-yl)phenyl]-(3,4-dimethoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C1=CC=C(N2CCN(CC2)C2CCCC2)C=C1 TWLQBZJVBYJZPS-UHFFFAOYSA-N 0.000 claims 1
- ACUDYEDEHGVEKZ-UHFFFAOYSA-N [4-[4-(cyclopropylmethyl)piperazin-1-yl]-3,5-difluorophenyl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)C(C=C1F)=CC(F)=C1N1CCN(CC2CC2)CC1 ACUDYEDEHGVEKZ-UHFFFAOYSA-N 0.000 claims 1
- PXGWRWMNLVKGTJ-UHFFFAOYSA-N [4-[4-(cyclopropylmethyl)piperazin-1-yl]-3,5-difluorophenyl]-phenylmethanone Chemical compound FC1=CC(C(=O)C=2C=CC=CC=2)=CC(F)=C1N(CC1)CCN1CC1CC1 PXGWRWMNLVKGTJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000014679 binge eating disease Diseases 0.000 claims 1
- GVCWILDLGZCPSF-UHFFFAOYSA-N cyclopropyl-[4-(4-pentan-3-ylpiperazin-1-yl)phenyl]methanone Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(C(=O)C2CC2)C=C1 GVCWILDLGZCPSF-UHFFFAOYSA-N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- ZUGDWIGHTLXJCC-UHFFFAOYSA-N n-benzyl-n-methyl-6-(4-pentan-3-ylpiperazin-1-yl)pyridine-3-carboxamide Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(C(=O)N(C)CC=2C=CC=CC=2)C=N1 ZUGDWIGHTLXJCC-UHFFFAOYSA-N 0.000 claims 1
- FMXXCKCIVXGUNS-UHFFFAOYSA-N n-methyl-6-(4-pentan-3-ylpiperazin-1-yl)-n-phenylpyridine-3-carboxamide Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(C(=O)N(C)C=2C=CC=CC=2)C=N1 FMXXCKCIVXGUNS-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003382 histamine H3 receptor agonist Substances 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 239000002469 receptor inverse agonist Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- TVPBYBLCQIKDAB-UHFFFAOYSA-N (2-chlorophenyl)-[4-(4-pentan-3-ylpiperazin-1-yl)phenyl]methanone Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(C(=O)C=2C(=CC=CC=2)Cl)C=C1 TVPBYBLCQIKDAB-UHFFFAOYSA-N 0.000 description 1
- NSIYIZDVZLGOES-UHFFFAOYSA-N (4-hydroxyphenyl)-[4-(4-pentan-3-ylpiperazin-1-yl)phenyl]methanone Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(C(=O)C=2C=CC(O)=CC=2)C=C1 NSIYIZDVZLGOES-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- NKQJLSMBFNZKDZ-UHFFFAOYSA-N 6-methoxy-2-(4-propan-2-ylpiperazin-1-yl)quinoline Chemical compound C1=CC2=CC(OC)=CC=C2N=C1N1CCN(C(C)C)CC1 NKQJLSMBFNZKDZ-UHFFFAOYSA-N 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 1
- 229940121914 Histamine H3 receptor agonist Drugs 0.000 description 1
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 description 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 description 1
- 101001016833 Homo sapiens Histamine H3 receptor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- RWHZTGSQLHURNF-UHFFFAOYSA-N [2-(4-pentan-3-ylpiperazin-1-yl)pyridin-4-yl]-phenylmethanone Chemical compound C1CN(C(CC)CC)CCN1C1=CC(C(=O)C=2C=CC=CC=2)=CC=N1 RWHZTGSQLHURNF-UHFFFAOYSA-N 0.000 description 1
- LQFRDHQHEKQLFT-UHFFFAOYSA-N [6-(4-pentan-3-ylpiperazin-1-yl)pyridin-3-yl]-piperidin-1-ylmethanone Chemical compound C1CN(C(CC)CC)CCN1C1=CC=C(C(=O)N2CCCCC2)C=N1 LQFRDHQHEKQLFT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000006640 cycloheptyl carbonyl group Chemical group 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000006641 cyclooctyl carbonyl group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940124806 histamine H3 agonist Drugs 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200200168 | 2002-02-05 | ||
US35663002P | 2002-02-08 | 2002-02-08 | |
US39930402P | 2002-07-26 | 2002-07-26 | |
DKPA200201142 | 2002-07-26 | ||
PCT/DK2003/000071 WO2003066604A2 (fr) | 2002-02-05 | 2003-02-05 | Nouvelles aryl- et heteroarylpiperazines |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200405694B true ZA200405694B (en) | 2005-09-28 |
Family
ID=27739216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2004/05694A ZA200405694B (en) | 2002-02-05 | 2004-07-16 | Novel aryl-and heteroarylpiperazines |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1474401A2 (fr) |
JP (1) | JP4607458B2 (fr) |
CN (1) | CN1628109A (fr) |
AU (2) | AU2003203148A1 (fr) |
BR (1) | BR0307429A (fr) |
CA (1) | CA2474214A1 (fr) |
IL (1) | IL162859A0 (fr) |
MX (1) | MXPA04007612A (fr) |
NO (1) | NO328714B1 (fr) |
PL (1) | PL372390A1 (fr) |
WO (1) | WO2003066604A2 (fr) |
ZA (1) | ZA200405694B (fr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7390813B1 (en) | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
EP1556046A1 (fr) | 2002-10-23 | 2005-07-27 | Janssen Pharmaceutica N.V. | Phenylpiperidines et phenylpyrrolidines utilisees comme modulateurs du recepteur h3 de l'histamine |
AU2004259263B2 (en) | 2003-07-29 | 2010-12-16 | High Point Pharmaceuticals, Llc | Pyridazinyl- piperazines and their use as histamine H3 receptor ligands |
RU2006105716A (ru) * | 2003-07-30 | 2007-09-10 | Зинон Фармасьютиклз Инк. (Ca) | Производные пиридазина и их применение в качестве терапевтических средств |
US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
BRPI0412352A (pt) | 2003-07-30 | 2006-09-05 | Xenon Pharmaceuticals Inc | processo para a preparação de derivados de tetrazol de azidas de organo boro e organo alumìnio |
TWI345974B (en) | 2003-07-30 | 2011-08-01 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase |
WO2005035521A1 (fr) * | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Quinoleines substituees, utilisees comme modulateurs de la mch |
GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
JP4596792B2 (ja) * | 2004-02-24 | 2010-12-15 | あすか製薬株式会社 | 5−ht1a作動作用と5−ht3拮抗作用を併有する薬剤 |
CA2561791A1 (fr) * | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Composes heterocycliques non-imidazole |
EP2305352A1 (fr) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques |
US20050256309A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
MXPA06015267A (es) * | 2004-06-22 | 2007-03-15 | Pfizer Prod Inc | Antagonistas diazabiciclicos del receptor histamina-3. |
CA2580857A1 (fr) * | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques |
EP1807085B1 (fr) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques |
CA2580781A1 (fr) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques bicycliques et leur utilisation comme inhibiteurs de stearoyl-coa desaturase (scd) |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
MX2007003330A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
JP5094398B2 (ja) | 2004-09-20 | 2012-12-12 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環式誘導体およびステアロイル−CoAデサチュラーゼのメディエータとしてのそれらの使用 |
BRPI0515489A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase |
CN101083992A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物 |
ES2543813T3 (es) * | 2004-11-02 | 2015-08-24 | Northwestern University | Compuestos de piridazina para el tratamiento de enfermedades inflamatorias |
US7700595B2 (en) | 2005-03-01 | 2010-04-20 | Wyeth Llc | Cinnoline compounds |
WO2007130075A1 (fr) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine |
ES2375929T3 (es) | 2005-07-04 | 2012-03-07 | High Point Pharmaceuticals, Llc | Antagonistas del receptor histamina h3. |
JP4787321B2 (ja) * | 2005-07-05 | 2011-10-05 | エフ.ホフマン−ラ ロシュ アーゲー | ピリダジン誘導体 |
US8686002B2 (en) | 2005-08-21 | 2014-04-01 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as binding partners for 5-HT5 receptors |
GB0517184D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
ATE463481T1 (de) * | 2005-09-16 | 2010-04-15 | Janssen Pharmaceutica Nv | Cyclopropylamine als modulatoren des histamin-h3- rezeptors |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
CN101410385B (zh) | 2006-03-28 | 2011-08-24 | 高点制药有限责任公司 | 具有组胺h3受体活性的苯并噻唑类 |
CA2650625A1 (fr) * | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations contenant un compose de pyridazine |
JP2009537596A (ja) | 2006-05-23 | 2009-10-29 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用 |
SG163547A1 (en) | 2006-05-29 | 2010-08-30 | High Point Pharmaceuticals Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
CN101495456B (zh) | 2006-05-30 | 2014-03-19 | 詹森药业有限公司 | 作为组胺h3受体的调节剂的取代的吡啶基酰胺化合物 |
CN101448820A (zh) * | 2006-05-30 | 2009-06-03 | 霍夫曼-拉罗奇有限公司 | 哌啶基嘧啶衍生物 |
WO2007150010A2 (fr) | 2006-06-23 | 2007-12-27 | Abbott Laboratories | Dérivés de cyclopropylamines |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
WO2008003702A2 (fr) * | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Quinazolines et composés hétérocycliques associés, et leur utilisation dans le domaine thérapeutique |
JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
JO2849B1 (en) * | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
DK2148873T3 (da) | 2007-04-23 | 2012-11-26 | Janssen Pharmaceutica Nv | 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister |
EP2148879B1 (fr) | 2007-04-23 | 2012-11-28 | Janssen Pharmaceutica, N.V. | Thia(dia)zoles en tant qu'antagonistes du récepteur de la dopamine à dissociation rapide |
JP5603770B2 (ja) * | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2受容体拮抗薬およびその使用 |
EP2014656A3 (fr) * | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | Nouveaux antagonistes d'hétéocycliques h3 |
KR20100039429A (ko) * | 2007-08-02 | 2010-04-15 | 에프. 호프만-라 로슈 아게 | Cns 질환의 치료를 위한 벤즈아미드 유도체의 용도 |
ES2384414T3 (es) | 2007-09-06 | 2012-07-04 | Glaxo Group Limited | Derivado de piperazina que tiene afinidad por el receptor H3 de histamina |
MY158253A (en) | 2007-11-20 | 2016-09-30 | Janssen Pharmaceutica Nv | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor |
WO2009079593A1 (fr) * | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Dérivés pipérazinyle utiles comme modulateurs du récepteur du neuropeptide y2 |
US20120129870A1 (en) * | 2007-12-17 | 2012-05-24 | Wenying Chai | Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor |
CN102159554B (zh) | 2008-07-03 | 2014-09-24 | 詹森药业有限公司 | 作为5-ht6受体拮抗剂的取代的6-(1-哌嗪基)-哒嗪 |
EA019048B1 (ru) | 2008-07-31 | 2013-12-30 | Янссен Фармацевтика Нв | Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина |
PE20120061A1 (es) | 2008-12-19 | 2012-02-19 | Boehringer Ingelheim Int | Derivados de pirimidina como antagonistas del receptor ccr2 |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
BR112012015873B1 (pt) | 2009-12-17 | 2021-06-01 | Centrexion Therapeutics Corporation | Antagonistas de receptores ccr2 |
TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基-雜芳基衍生物及其使用方法 |
US8877745B2 (en) | 2010-05-12 | 2014-11-04 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
WO2011141477A1 (fr) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Nouveaux antagonistes du récepteur ccr2, leur procédé de production et leur utilisation en tant que médicaments |
JP5647339B2 (ja) | 2010-05-17 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2アンタゴニスト及びこれらの使用 |
JP5636094B2 (ja) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2受容体アンタゴニスト |
WO2011151251A1 (fr) | 2010-06-01 | 2011-12-08 | Boehringer Ingelheim International Gmbh | Nouveaux antagonistes du ccr2 |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
WO2013010839A1 (fr) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Antagonistes de ccr2 nouveaux et sélectifs |
WO2013151982A1 (fr) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés |
BR112017002214B1 (pt) | 2014-08-04 | 2023-03-07 | Nuevolution A/S | Composto de fórmula (i), e uso de um composto |
BR112017028492B1 (pt) | 2015-07-02 | 2023-12-26 | Centrexion Therapeutics Corporation | Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica |
AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021198956A1 (fr) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Composés actifs vis-à-vis des récepteurs nucléaires |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB753166A (en) * | 1953-05-22 | 1956-07-18 | Miles Lab | Improvements in or relating to substituted piperazines |
US2993899A (en) * | 1958-03-31 | 1961-07-25 | Miles Lab | Acetylenically unsaturated piperazine derivatives |
US3309370A (en) * | 1964-07-16 | 1967-03-14 | Miles Lab | Bicycloalkyl piperazine derivatives and process |
FR2306694A1 (fr) * | 1975-04-07 | 1976-11-05 | Parcor | Derives de la piperazine |
US4144346A (en) * | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
US4163849A (en) * | 1978-03-17 | 1979-08-07 | Merck & Co., Inc. | Piperazinylpyrazines |
JPS56118074A (en) * | 1980-02-22 | 1981-09-16 | Tanabe Seiyaku Co Ltd | Propane derivative and its preparation |
US4339579A (en) * | 1980-12-29 | 1982-07-13 | American Home Products Corporation | 2,6-Bis-(pyrrolopyrazinyl)pyrazines |
US5001125A (en) * | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
FR2573075B1 (fr) * | 1984-09-14 | 1987-03-20 | Innothera Lab Sa | Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique |
DK111387A (da) * | 1986-03-05 | 1987-09-06 | Otsuka Pharma Co Ltd | Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne |
JP2576862B2 (ja) * | 1986-03-05 | 1997-01-29 | 大塚製薬 株式会社 | カルボスチリル誘導体 |
AU639529B2 (en) * | 1987-03-04 | 1993-07-29 | Higuchi, Yoshinari | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
DE3803860A1 (de) * | 1988-02-09 | 1989-08-17 | Basf Ag | N,n'-disubstituierte piperazine |
US5021421A (en) * | 1989-03-03 | 1991-06-04 | Dainippon Pharmaceutical Co., Ltd. | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same |
GB9012316D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
WO1997002245A1 (fr) * | 1995-07-06 | 1997-01-23 | Japan Tobacco Inc. | Derives de benzamidoxime et leur utilisation a des fins medicinales |
JPH0971564A (ja) * | 1995-07-06 | 1997-03-18 | Japan Tobacco Inc | ベンズアミドオキシム誘導体及びその医薬用途 |
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
EP1020445B1 (fr) * | 1997-10-02 | 2008-08-13 | Eisai R&D Management Co., Ltd. | Derives de pyridine condenses |
JP3989102B2 (ja) * | 1997-10-02 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合ピリジン誘導体 |
WO2000066578A1 (fr) * | 1999-04-30 | 2000-11-09 | Pfizer Products Inc. | Composes pour le traitement de l'obesite |
GB9926303D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
ES2243337T3 (es) * | 1999-12-16 | 2005-12-01 | Schering Corporation | Imidazoles sustituidos antagonistas del receptor y5 del neuropeptido y. |
FI20000480A0 (fi) * | 2000-03-01 | 2000-03-01 | Orion Yhtymae Oyj | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
HUP0401858A3 (en) * | 2001-01-31 | 2009-06-29 | Lundbeck & Co As H | Gal3 receptor antagonist pyrimidine and indolone-derivatives and their use for preparation of pharmaceutical compositions suitable for the treatment of depression and/or anxiety |
AU2003229535A1 (en) * | 2002-06-06 | 2003-12-22 | Novo Nordisk A/S | Substituted hexahydropyrrolo(1,2-a)pyrazines, octahydropyrido(1,2-a)pyrazines and decahydropyrazino(1,2-a)azepines |
-
2003
- 2003-02-05 AU AU2003203148A patent/AU2003203148A1/en not_active Abandoned
- 2003-02-05 JP JP2003565978A patent/JP4607458B2/ja not_active Expired - Fee Related
- 2003-02-05 MX MXPA04007612A patent/MXPA04007612A/es not_active Application Discontinuation
- 2003-02-05 BR BR0307429-3A patent/BR0307429A/pt not_active Application Discontinuation
- 2003-02-05 CA CA002474214A patent/CA2474214A1/fr not_active Abandoned
- 2003-02-05 CN CNA038033607A patent/CN1628109A/zh active Pending
- 2003-02-05 IL IL16285903A patent/IL162859A0/xx unknown
- 2003-02-05 EP EP03701482A patent/EP1474401A2/fr not_active Withdrawn
- 2003-02-05 PL PL03372390A patent/PL372390A1/xx not_active Application Discontinuation
- 2003-02-05 WO PCT/DK2003/000071 patent/WO2003066604A2/fr active Application Filing
-
2004
- 2004-07-16 ZA ZA2004/05694A patent/ZA200405694B/en unknown
- 2004-09-03 NO NO20043709A patent/NO328714B1/no not_active IP Right Cessation
-
2010
- 2010-01-13 AU AU2010200135A patent/AU2010200135A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1474401A2 (fr) | 2004-11-10 |
AU2010200135A1 (en) | 2010-02-04 |
JP2005533747A (ja) | 2005-11-10 |
NO328714B1 (no) | 2010-05-03 |
JP4607458B2 (ja) | 2011-01-05 |
MXPA04007612A (es) | 2004-11-10 |
WO2003066604A3 (fr) | 2003-12-04 |
AU2003203148A1 (en) | 2003-09-02 |
PL372390A1 (en) | 2005-07-25 |
NO20043709L (no) | 2004-09-03 |
BR0307429A (pt) | 2004-12-28 |
CA2474214A1 (fr) | 2003-08-14 |
CN1628109A (zh) | 2005-06-15 |
IL162859A0 (en) | 2005-11-20 |
WO2003066604A2 (fr) | 2003-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200405694B (en) | Novel aryl-and heteroarylpiperazines | |
US10717739B2 (en) | Methods and compositions for inhibition of bromodomain-containing proteins | |
CA2807620C (fr) | Composes pharmaceutiquement actifs en tant qu'inhibiteurs de axl | |
CA2806332C (fr) | Derives de quinoline et inhibiteurs de melk les contenant | |
JP5797345B2 (ja) | プロテインキナーゼに対する阻害活性を有するチエノ[3,2−d]ピリミジン誘導体 | |
WO2015002754A2 (fr) | Nouveaux inhibiteurs de bromodomaines bicycliques | |
CN102448920B (zh) | 抗病毒化合物和其用途 | |
EP1835934A2 (fr) | Modulateurs d'enzymes et traitements | |
JP2020512343A5 (fr) | ||
TW200900064A (en) | Pyrrole compounds | |
US20080139558A1 (en) | Quinolones useful as inducible nitric oxide synthase inhibitors | |
ZA200305619B (en) | Substituted triazole diamine derivatives as kinase inhibitors. | |
CA2456817A1 (fr) | Derives de l'alkyne-aryl-naphthyridin-4 (1h)-one en tant qu'inhibiteurs de la phosphodiesterase de type iv | |
BRPI0609928A2 (pt) | inibidores de quinase tpl-2 de 3-cianoquinolina e métodos de fabricação e uso dos mesmos | |
TW200800185A (en) | Acid secretion inhibitor | |
HRP20130865T1 (hr) | Derivati pirazol piridina kao inhibitori nadph oksidaze | |
CN108864151A (zh) | 杂环胺及其用途 | |
JP2012510989A5 (fr) | ||
RU2006106272A (ru) | Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae | |
HU228961B1 (en) | Triazinones and their use as active ingredients of pharmaceutical compositions | |
JP2013501749A5 (fr) | ||
ZA200405632B (en) | Amides of aminoalkyl substituted azetidines pyrrolidines and azepanes | |
NZ590954A (en) | Compounds as kinase inhibitors | |
CN110357789A (zh) | 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途 | |
EP1492773B1 (fr) | 4-(heterocyclyl)-benzenesulfoximines, leur procede de preparation, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de maladies inflammatoires |